Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.50 |
| ▸ | TDO2 | P48775 | 10/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22387682 | 1.00 | IDO1 (0.50) | IDO1TDO2CYP2C9CYP2C8CYP3A4 | |
| SCHEMBL22270489 | 1.00 | IDO1 (0.50) | IDO1TDO2CYP2C9CYP2C8CYP3A4 | |
| SCHEMBL22387401 | 1.00 | IDO1 (0.50) | IDO1TDO2CYP2C9CYP2C8CYP3A4 | |
| SCHEMBL22387743 | 1.00 | IDO1 (0.50) | IDO1TDO2CYP2C9CYP2C8CYP3A4 | |
| SCHEMBL22387402 | 1.00 | IDO1 (0.50) | IDO1TDO2CYP2C9CYP2C8CYP3A4 | |
| SCHEMBL22270914 | 0.91 | IDO1 (0.61) | IDO1TDO2CYP2C9CYP2C8CYP3A4 | |
| SCHEMBL22387668 | 0.91 | IDO1 (0.61) | IDO1TDO2CYP2C9CYP2C8CYP3A4 | |
| SCHEMBL22270486 | 0.91 | IDO1 (0.61) | IDO1TDO2CYP2C9CYP2C8CYP3A4 | |
| SCHEMBL22387503 | 0.90 | IDO1 (0.44) | IDO1TDO2CYP2C9CYP2C8CYP3A4 | |
| SCHEMBL21475837 | 0.89 | IDO1 (0.56) | IDO1TDO2CYP2C9CYP2C8CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686196-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | Hangzhou Innogate Pharma Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |